公开(公告)号：US20240240146A1

公开(公告)日：2024-07-18

申请号：US18410900

申请日：2024-01-11

申请人： Iovance Biotherapeutics, Inc.

发明人： Seth Wardell ,  Maritza Lienlaf Moreno

IPC分类号： C12N5/0783 ,  A61K9/00 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07K16/28

CPC分类号： C12N5/0638 ,  A61K9/0019 ,  A61K35/17 ,  A61K38/2013 ,  A61P35/00 ,  C07K16/2809 ,  C12N2501/2302 ,  C12N2502/11

摘要： The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

公开(公告)号：US12036271B2

公开(公告)日：2024-07-16

申请号：US17838017

申请日：2022-06-10

申请人： Immatics Biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Anita Wiebe ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC分类号： A61K38/08 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K38/08 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K14/70539 ,  C07K16/2833 ,  C12N5/0638 ,  C12N15/115 ,  A61K2039/5158 ,  C07K2319/00 ,  C12N2310/16 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/51 ,  C12N2501/515

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12036241B2

公开(公告)日：2024-07-16

申请号：US16631781

申请日：2018-07-19

申请人： Fate Therapeutics, Inc. ,  Juno Therapeutics, Inc.

发明人： Jonathan Rosen ,  Eigen Peralta ,  Ian Hardy ,  Betsy D. Rezner ,  Christian Maine ,  Daniel Shoemaker ,  David Robbins ,  Lucas Thompson

IPC分类号： A61K35/17 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0636 ,  C12N5/0646 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2510/00

摘要： Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.

公开(公告)号：US20240228959A9

公开(公告)日：2024-07-11

申请号：US18377685

申请日：2023-10-06

申请人： Kite Pharma, Inc.

发明人： Felipe Bedoya ,  David Barrett ,  Vijay Gopal Reddy Peddareddigari ,  Namrata Choudhari ,  Matthew VanPelt

IPC分类号： C12N5/0783 ,  C12N5/00 ,  C12N15/86

CPC分类号： C12N5/0636 ,  C12N5/0031 ,  C12N15/86 ,  C12N2527/00 ,  C12N2740/10043 ,  C12N2740/15043

摘要： The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.

公开(公告)号：US20240228645A1

公开(公告)日：2024-07-11

申请号：US18620375

申请日：2024-03-28

申请人： Dragonfly Therapeutics, Inc.

发明人： Benjamin FISCHER ,  Pyae P. HEIN ,  Alexander IVANOV ,  Xinbi LI ,  Matthew SCHNEIDER

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  C07K14/525 ,  C07K14/54 ,  C07K14/55 ,  C07K14/56 ,  C12N5/0783

CPC分类号： C07K16/2878 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/4633 ,  A61K39/4643 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/68035 ,  A61K47/68037 ,  A61K47/6807 ,  A61K47/6849 ,  C07K14/525 ,  C07K14/5406 ,  C07K14/5428 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/56 ,  C07K16/2809 ,  C12N5/0636 ,  C12N5/0646 ,  C07K2317/31 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting BAFF-R on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer or autoimmune disease.

公开(公告)号：US20240228636A1

公开(公告)日：2024-07-11

申请号：US18481797

申请日：2023-10-05

申请人： Cellectis ,  Allogene Therapeutics, Inc.

发明人： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  G01N15/01 ,  G01N15/10 ,  G01N15/1031 ,  G01N15/14 ,  G01N15/149

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001176 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  G01N15/1031 ,  G01N15/14 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  G01N2015/016 ,  G01N2015/1006 ,  G01N2015/1028 ,  G01N15/149

摘要： A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US20240228580A1

公开(公告)日：2024-07-11

申请号：US18405778

申请日：2024-01-05

申请人： University of Kentucky Research Foundation

发明人： Jill M. Kolesar ,  Christopher I. Richards

IPC分类号： C07K14/74 ,  A61K9/127 ,  A61K35/15 ,  C12N5/0783 ,  C12N5/0784

CPC分类号： C07K14/70539 ,  A61K9/127 ,  A61K35/15 ,  C12N5/0636 ,  C12N5/0639

摘要： An antigen-presenting dendritic cell membrane derived nanovesicle (CDNV) can be made by incubating a dendritic cell (DC) with an antigen and an agent to activate the DC, thereby generating a mature DC displaying a major histocompatibility complex class I (MHC) presenting the antigen, and fragmenting the membrane of the mature DC and allowing the fragmented membrane to assemble into a CDNV displaying the MHC presenting the antigen. The CDNV can be delivered to an environment including a T cell, thereby directly activating the T cell, or indirectly activating the T cell through a bystander antigen presenting cell (APC) that uptakes the CDNV and presents the antigen. The activated T cell and produce a T cell response.

公开(公告)号：US20240226295A9

公开(公告)日：2024-07-11

申请号：US18546384

申请日：2022-02-15

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Chantal KUHN ,  Gary SHAPIRO

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61P35/00 ,  A61P37/02 ,  C12N5/0783 ,  C12N15/63

CPC分类号： A61K39/4631 ,  A61K35/17 ,  A61P35/00 ,  A61P37/02 ,  C12N5/0636 ,  C12N15/63 ,  A61K2239/11 ,  A61K2239/21 ,  A61K2239/22 ,  C12N2510/00

摘要： Methods of using polypeptides to modulate transforming growth factor-β (TGFβ) signaling (e.g., TGFβ receptors, antibodies or antigen-binding fragments thereof that specifically bind TGFβ or a TGFβ receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGFβ activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGFβ signaling modulators are provided herein.

公开(公告)号：US20240226161A9

公开(公告)日：2024-07-11

申请号：US18546936

申请日：2022-02-18

申请人： Memorial Sloan-Kettering Cancer Center ,  Sloan-Kettering Institute for Cancer Research ,  Memorial Hospital for Cancer and Allied Diseases

发明人： Morgan HUSE ,  Minggang ZHANG

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C12N5/0783 ,  C12N15/113 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464466 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C12N5/0636 ,  C12N15/113 ,  C12N15/86 ,  A61K2239/31 ,  C12N2310/141 ,  C12N2740/10043

摘要： Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress miR200c and/or EpCAM.

公开(公告)号：US12031146B2

公开(公告)日：2024-07-09

申请号：US17322561

申请日：2021-05-17

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Adi Barzel ,  Mark A. Kay

IPC分类号： A61K39/00 ,  A61K38/18 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/10 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/64 ,  C12N15/00 ,  C12N15/52 ,  C12N15/86 ,  C12N15/90

CPC分类号： C12N15/86 ,  A61K38/1866 ,  A61K48/0008 ,  A61K48/005 ,  C07K16/1045 ,  C12N9/644 ,  C12N15/52 ,  C12N15/907 ,  C12Y304/21022 ,  C07K2317/76 ,  C07K2319/92 ,  C12N2750/14143 ,  C12N2799/025 ,  C12N2800/24 ,  C12N2840/20 ,  Y02A50/30

摘要： Methods and compositions are provided for editing the genome of a cell without the use of an exogenously supplied nuclease. Aspects of the methods include contacting a cell with a targeting vector comprising nucleic acid sequence to be integrated into the target locus, where the cell is not also contacted with a nuclease. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided.